ArticleCureus2025
Prevalence of Chronic Myocardial Ischemia and Gastrointestinal Bleeding Risk in Patients With Chronic Kidney Disease Undergoing Dual Antiplatelet Therapy.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Antithrombotic Therapy After PCI in High-Risk Cardiovascular Patients: Navigating Complexity Beyond Guidelines.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Chronic kidney disease (CKD) is strongly associated with an increased risk of cardiovascular morbidity and mortality, with chronic myocardial ischemia being a frequent complication. Objective The objective of this study is to determine the prevalence of chronic myocardial ischemia and evaluate the gastrointestinal bleeding risk in CKD patients receiving dual antiplatelet therapy. Methods This cross-sectional observational study was conducted at the Dow University of Health and Sciences in Karachi between January and July 2025. A total of 180 patients with diagnosed CKD who were undergoing dual antiplatelet therapy were chosen for the study. Clinical assessment, laboratory parameters, and electrocardiographic findings were used to evaluate chronic myocardial ischemia. Gastrointestinal bleeding risk was assessed through clinical history, endoscopic evaluation (when indicated), and validated bleeding risk scores. Results Among 180 CKD patients, 74 (41.1%) demonstrated evidence of chronic myocardial ischemia on ECG and clinical evaluation. Gastrointestinal bleeding events were documented in 32 (17.8%) patients, while an additional 46 (25.6%) were classified as high risk for bleeding based on clinical and endoscopic assessment. Patients in advanced CKD stages (Stage 4 and 5, n=110) had a significantly higher prevalence of myocardial ischemia (57/110, 51.8%) and gastrointestinal bleeding risk (31/110, 28.2%) compared to those in earlier stage CKD (Stage 3, n=70; ischemia 20/70, 28.6%; bleeding risk 12/70, 17.1%) (p<0.05). Conclusion Chronic myocardial ischemia and gastrointestinal bleeding risk are both highly prevalent in CKD patients undergoing dual antiplatelet therapy. Nearly half of the patients exhibited ischemic burden, while one-fifth experienced bleeding events.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.